Please login to the form below

Not currently logged in
Email:
Password:

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

NICEThe UK's cost-effectiveness body has for the first time included biosimilar drugs in new guidance on the use of biologics in severe rheumatoid arthritis.

The final guidance - published yesterday - recommends seven biologic disease-modifying anti-rheumatic drugs (DMARDs) and two biosimilars and is in line with draft guidance published last September.

The recommended brands are: AbbVie's Humira (adalimumab), Pfizer's Enbrel (etanercept), UCB's Cimzia (certolizumab pegol), MSD/Johnson & Johnson's Simponi (golimumab), Roche's RoActemra (tocilizumab), Bristol-Myers Squibb's Orencia (abatacept) and MSD/J&J's Remicade (infliximab).

Also backed are Napp Pharmaceuticals' Remsima and Pfizer's Inflectra, both of which are biosimilar versions of $10bn-a-year brand Remicade and cost around 10% less than the originator drug at list prices.  However, it is understood that the biosimilars are being supplied at an undisclosed discount to the NHS.

As their name suggests, biosimilars are copies of biologic drugs that are similar but not identical to the original medicine, but are considered therapeutically equivalent.

Importantly, NICE says treatment should be started "with the least expensive drug", taking into account administration costs, the dose needed and the price of the drug per dose, suggesting there will be pressure on NHS prescribers to opt for the cheaper biosimilars.

All the drugs are recommended for use alongside methotrexate, while Humira, Enbrel, Cimzia and RoActemra are also backed for use on their own in patients who cannot tolerate the conventional DMARD.

"This guidance considers at which stage it's clinically and cost effective to start using biological therapies as treatment options for adults with rheumatoid arthritis," said Professor Carole Longson, director of the Health Technology Evaluation Centre at NICE.

The guidance only applies to patients with severe RA who have already tried earlier treatment with methotrexate and other conventional DMARDs as well as short-term corticosteroid therapy.

Article by
Phil Taylor

27th February 2015

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
FCB Halesway

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

OUTiCO Case Study - Product Launch
POSITIVE FORMULARY SUCCESS WITHIN 8 MONTHS!...
An insight into Multi-Channel Account Management
At OUTiCO we often talk about moving away from traditional methods, embracing change, and offering an exceptional outsourcing service, but what does that mean day to day?...
14_ipad_lowres.jpg
Why AI might be the rep’s best friend
When looking for the next big thing in digital communication, there’s nothing bigger than the sweeping changes promised by artificial intelligence. There’s little doubt that AI is coming to pharma...

Infographics